Firms

Founded

—

Type

Venture capital

Team

No team members on record yet.

Co-investing

ARCH Venture Partners

• Prime Medicine, Inc.$200M · 2021-07-13
• OncoResponse, Inc.$40M · 2021
• OncoResponse, Inc.$40M · 2018-09-11
• OncoResponse$40M · 2018-09-11
• Syros Pharmaceuticals$53M · 2014-10-27

Canaan Partners

• OncoResponse, Inc.$40M · 2021
• OncoResponse, Inc.$40M · 2018-09-11
• OncoResponse$40M · 2018-09-11

RiverVest Venture Partners

• OncoResponse, Inc.$40M · 2021
• OncoResponse, Inc.$40M · 2018-09-11
• OncoResponse$40M · 2018-09-11

Alexandria Venture Investments

• OncoResponse, Inc.$40M · 2018-09-11
• OncoResponse$40M · 2018-09-11

Khosla Ventures

• Genalyte$50M · 2021-01-11
• Genalyte$36M · 2016-11-21

SHOW MORE

Investments

$200M2021-07-13	Prime Medicine, Inc.	ARCH Venture Partners, F-Prime Capital, GV, Newpath Partners, Casdin Capital, Cormorant Asset Management, Moore Strategic Ventures, PSP Investments, Redmile Group, Samsara BioCapital, T. Rowe Price Associates
$50M2021-01-11	Genalyte	Khosla Ventures, Verily, Redmile Group, HBM Healthcare Investments, Provenio Capital
$40M2021	OncoResponse, Inc.	ARCH Venture Partners, Canaan Partners, Redmile Group, RiverVest Venture Partners, 3B Future Health Fund, Magnetar Capital
$40M2018-09-11	OncoResponse, Inc.	ARCH Venture Partners, Alexandria Venture Investments, Canaan Partners, Qatar Investment Authority, Redmile Group, RiverVest Venture Partners
$40M2018-09-11	OncoResponse	ARCH Venture Partners, Alexandria Venture Investments, Canaan Partners, Qatar Investment Authority, Redmile Group, RiverVest Venture Partners
$36M2016-11-21	Genalyte	Khosla Ventures, Redmile Group
$53M2014-10-27	Syros Pharmaceuticals	ARCH Venture Partners, Polaris Partners, Redmile Group

SHOW MORE